American Renal Associates Holdings, Inc (NYSE:ARA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, July 12th.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Separately, Wells Fargo & Company raised American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. American Renal Associates Holdings presently has a consensus rating of “Buy” and an average price target of $25.50.

Shares of American Renal Associates Holdings (NYSE ARA) traded down 2.89% during mid-day trading on Wednesday, reaching $15.10. The company’s stock had a trading volume of 244,199 shares. The firm’s market cap is $470.38 million. The company has a 50-day moving average of $18.11 and a 200-day moving average of $18.36. American Renal Associates Holdings has a 12 month low of $14.92 and a 12 month high of $25.42.

American Renal Associates Holdings (NYSE:ARA) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $0.06 EPS for the quarter, missing the Zacks’ consensus estimate of $0.10 by $0.04. American Renal Associates Holdings had a negative net margin of 2.13% and a positive return on equity of 20.97%. The firm had revenue of $177 million for the quarter, compared to analyst estimates of $184.67 million. During the same period in the previous year, the business posted $0.16 earnings per share. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. On average, analysts predict that American Renal Associates Holdings will post $0.53 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “American Renal Associates Holdings, Inc (NYSE:ARA) Downgraded to “Hold” at Zacks Investment Research” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/07/zacks-investment-research-downgrades-american-renal-associates-holdings-inc-nyseara-to-hold-updated-updated-updated.html.

Institutional investors have recently bought and sold shares of the company. Atria Investments LLC bought a new position in American Renal Associates Holdings during the first quarter worth approximately $181,000. Oxford Asset Management bought a new position in American Renal Associates Holdings during the first quarter worth approximately $237,000. Rhumbline Advisers raised its position in American Renal Associates Holdings by 2.7% in the second quarter. Rhumbline Advisers now owns 13,383 shares of the company’s stock worth $248,000 after buying an additional 354 shares in the last quarter. Lucus Advisors LLC bought a new position in American Renal Associates Holdings during the first quarter worth approximately $295,000. Finally, Martingale Asset Management L P bought a new position in American Renal Associates Holdings during the first quarter worth approximately $372,000. 88.83% of the stock is currently owned by institutional investors.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates Holdings (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for American Renal Associates Holdings (NYSE:ARA)

Receive News & Stock Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related stocks with our FREE daily email newsletter.